Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
-
PHILADELPHIA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies...
-
DSG3-CAART achieved autoantibody elimination and resolution of blisters in active immune mouse model of pemphigus vulgarisSoluble autoantibodies demonstrated potential to enhance DSG3-CAART efficacy...
-
PHILADELPHIA, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
-
PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
-
PHILADELPHIA and DENVER, July 07, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell...
-
Collaboration deepens pipeline with CAAR design and optimization effort in three additional B cell-mediated autoimmune diseases PHILADELPHIA, May 28, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc....
-
PHILADELPHIA, May 27, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...
-
In vivo preclinical data show that Chimeric AutoAntibody Receptor (CAAR) T cells were able to specifically recognize and eliminate anti-MuSK antibody-expressing B cells while sparing control B cells ...
-
PHILADELPHIA, May 12, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for...